The Role of T Cells Reactive to the Cathelicidin Antimicrobial Peptide LL-37 in Acute Coronary Syndrome and Plaque Calcification.
Chernomordik. Fernando F; Cercek. Bojan B; Lio. Wai Man WM; Mihailovic. Peter M PM; Yano. Juliana J; Herscovici. Romana R; Zhao. Xiaoning X; Zhou. Jianchang J; Chyu. Kuang-Yuh KY; Shah. Prediman K PK; Dimayuga. Paul C PC
Key Findings
- In patients with acute coronary syndrome, LL-37 fails to suppress CD8+ effector T‑cell activity, unlike in stable CAD or healthy controls.
- Adoptive transfer of LL-37‑reactive (mCRAMP) T cells into atherosclerotic mice reduced plaque area by about 28% and eliminated plaque calcification.
- LL-37‑reactive T cells showed higher IL‑10 and IFN‑γ expression, indicating a shift toward anti‑inflammatory and regulatory immune responses.
Practical Outcomes
- For biohackers, the main takeaway is that LL-37’s immune effects may influence heart‑related plaque formation, but there’s no clear, safe way to harness this for personal health. Until more applied research emerges, it’s best to focus on proven lifestyle and dietary strategies for cardiovascular health rather than trying to manipulate LL-37 directly.
Summary
Researchers found that a protein called LL-37, which the immune system can recognize, behaves differently in people having a heart attack compared to those with stable heart disease. In mouse experiments, immune cells that react to the mouse version of LL-37 helped shrink artery plaques and stopped them from turning into hard calcium deposits. The study suggests LL-37‑reactive immune cells might play a role in heart disease, but it doesn’t give any direct advice on using LL-37 as a supplement or treatment.
Abstract
The human cationic anti-microbial peptide LL-37 is a T cell self-antigen in patients with psoriasis, who have increased risk of cardiovascular events. However, the role of LL-37 as a T cell self-antigen in the context of atherosclerosis remains unclear. The objective of this study was to test for the presence of T cells reactive to LL-37 in patients with acute coronary syndrome (ACS). Furthermore, the role of T cells reactive to LL-37 in atherosclerosis was assessed using apoE-/- mice immunized with the LL-37 mouse ortholog, mCRAMP. Peripheral blood mononuclear cells (PBMCs) from patients with ACS were stimulated with LL-37. PBMCs from stable coronary artery disease (CAD) patients or self-reported subjects served as controls. T cell memory responses were analyzed with flow cytometry. Stimulation of PBMCs with LL-37 reduced CD8+ effector T cell responses in controls and patients with stable CAD but not in ACS and was associated with reduced programmed cell death protein 1 (PDCD1) mRNA expression. For the mouse studies, donor apoE-/- mice were immunized with mCRAMP or adjuvant as controls, then T cells were isolated and adoptively transferred into recipient apoE-/- mice fed a Western diet. Recipient mice were euthanized after 5 weeks. Whole aortas and hearts were collected for analysis of atherosclerotic plaques. Spleens were collected for flow cytometric and mRNA expression analysis. Adoptive transfer experiments in apoE-/- mice showed a 28% reduction in aortic plaque area in mCRAMP T cell recipient mice (P < 0.05). Fifty six percent of adjuvant T cell recipient mice showed calcification in atherosclerotic plaques, compared to none in the mCRAMP T cell recipient mice (Fisher's exact test <i>P</i> = 0.003). Recipients of T cells from mice immunized with mCRAMP had increased IL-10 and IFN-<b>γ</b> expression in CD8+ T cells compared to controls. In conclusion, the persistence of CD8+ effector T cell response in PBMCs from patients with ACS stimulated with LL-37 suggests that LL-37-reactive T cells may be involved in the acute event. Furthermore, studies in apoE-/- mice suggest that T cells reactive to mCRAMP are functionally active in atherosclerosis and may be involved in modulating plaque calcification.
Study Information
pubmed
2020
2020-10-06T00:00:00.000Z
10.3389/fimmu.2020.575577
12
48